DURHAM, NC, and LIEGE, BELGIUM - April 18, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has received new shareholding notifications following its issuance of new shares on April 8. As part of the private placement of $11.7 million the company closed on April 8, Rudi Mariën, one of Belgium's most successful life science entrepreneurs and investors, obtained a stake of 9 percent in the company through his investment company Biovest.

"We are proud that such a high caliber life science entrepreneur and investor has decided to back the new strategy we have laid out to capitalize on our world leading DNA methylation platform," said Dr. Jan Groen, chief executive officer of MDxHealth. "But almost equally important, as the former Managing Director of the Barc Group, a leading international centralized clinical laboratory, Mr. Mariën fully endorses our U.S. strategy, which rests on setting up our own CLIA lab and marketing and sales infrastructure."


"I feel privileged to become a major shareholder of MDxHealth. The company has accomplished an impressive turnaround over the past 12 months, and is now pursuing a strategy that can sustainably generate novel, high value molecular cancer diagnostics," said Rudi Mariën, President of Biovest. "I believe MDxHealth represents a classic value investment and I look forward to helping the company realize its potential."

Rudi Mariën was co-founder, reference shareholder and Chairman of Innogenetics, and has been the founder, shareholder and Managing Director of several clinical reference laboratories. He was also the founder, shareholder and former Managing Director of the Barc Group, a leading international centralized clinical laboratory, exclusively dedicated to pharmaceutical studies. He was the Vice President of Cerba European Lab and President and Managing Director of Gengest Bvba and Biovest CVA. Through his management company, Gengest BVBA, Mr Mariën has board mandates in different stocklisted and private biotech companies.

As per April 8, following the recent fundraising, MDxHealth had $23.5 million in cash and cash equivalents.

The shareholder notifications received following the April 8, 2011 capital increase are:


Shareholding after actively crossing the transparency threshold:

Biovest NV : 9.31%
Shareholdings after passively crossing the transparency threshold:

ING Belgium NV : 11.53%
Life Sciences Partners II BV : 7.58%
IDInvest Partners SA : 4.27%
APG Algemene Pensioen Groep NV : < 3%
BNP Paribas Fortis Investment Management : < 3%
About MDxHealth
MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company's tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research center such as Johns Hopkins University and Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Pfizer, and other industry leaders. More information can be found on the Company website: www.mdxhealth.com or on twitter at the following address : www.twitter.com/mdxhealth